1. Home
  2. ROC vs CGTX Comparison

ROC vs CGTX Comparison

Compare ROC & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rank One Computing Corporation Common stock

ROC

Rank One Computing Corporation Common stock

N/A

Current Price

$5.12

Market Cap

100.6M

Sector

N/A

ML Signal

N/A

Logo Cognition Therapeutics Inc.

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.10

Market Cap

102.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ROC
CGTX
Founded
2015
2007
Country
United States
United States
Employees
82
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
100.6M
102.9M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
ROC
CGTX
Price
$5.12
$1.10
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
3
Target Price
$9.00
$3.33
AVG Volume (30 Days)
66.3K
2.4M
Earning Date
03-31-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.71
$0.55
52 Week High
$7.80
$3.83

Technical Indicators

Market Signals
Indicator
ROC
CGTX
Relative Strength Index (RSI) 51.38 44.51
Support Level $4.42 $1.05
Resistance Level $5.32 $1.23
Average True Range (ATR) 0.60 0.17
MACD 0.03 -0.02
Stochastic Oscillator 62.61 19.88

Price Performance

Historical Comparison
ROC
CGTX

About ROC Rank One Computing Corporation Common stock

Rank One Computing Corp is an American artificial intelligence company. It develops AI systems that analyze visual data to identify and interpret objects and activities. The company's focus is on biometric identity, digital forensics, and real-time video analytics. It uses the term 'Vision AI,' which is an operational AI built for accuracy, speed, and auditability. The company generates revenue from the sale of access to its software platforms, maintenance services, and professional services.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: